fipThe International Pharmaceutical Federation (FIP) has appointed a new chief executive officer (CEO) Dr Catherine Duggan, to pilot the affairs of the organisation for the next administration.

The announcement of the new CEO was made on 7 February, in The Hague, Netherlands, via a press statement by the Federation.

Dr Duggan, whose tenure will commence from 1 June, 2018 is a pharmacist from the United Kingdom, and currently director of professional development at the Royal Pharmaceutical Society of Great Britain.

Expressing her delight towards the appointment, she pledged to take pharmacy worldwide to greater heights through credible established and new partnerships, while consolidating on the success of past leaderships of the organisation.

” I’m delighted and honoured to take up the position of CEO at FIP. I look forward to building on the great work of FIP leaders, past and present. To advance pharmacy worldwide, we will work through established partnerships with the World Health Organization and forge new partnerships at the global level to benefit the profession and the public,” she said.

The FIP President, Dr Carmen Peña has also expressed his pleasure towards the appointment Dr Duggan as the new FIP’s CEO. While he exhibited no doubt on the excellent representation of the organisation through Dr Duggan’s honesty, loyalty and energy, he said her appointment will fully project the values of the federation, fulfilling the objective of making FIP even stronger, bigger and more efficient.

He further stated that her excellent career so far makes her worthy of this tough but amazing position.

The document however stated clearly the obligations of the FIP’s CEO , where are: ensuring that the organisation, as the global voice of pharmaceutical practice, sciences and education, is an integral participant, on behalf of all its members, in global healthcare decisions and actions. In particular, the new CEO will lead the federation through its work to develop and implement a new strategy and vision.

 

Source: Pharmanews

Go to top